Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions

Sperti, 2005, F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a propective study, J Gastrointest Surg, 9, 22, 10.1016/j.gassur.2004.10.002

Sperti, 2003, 18-fluorodeoxyglucose positron emission predicting survival of patients with pancreatic carcinoma, J Gastrointest Surg, 7, 953, 10.1016/j.gassur.2003.09.002

Yoshioka, 2003, Positron emission tomography with 2-deoxy-2-fluoro-D-glucose for diagnosis of intraductal papillary mucinous tumor of the pancreas with parenchymal invasion, J Gastroenterol, 38, 1189, 10.1007/s00535-003-1230-8

Mansour, 2006, The utility of F-18-fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas, J Gastrointest Surg, 10, 1354, 10.1016/j.gassur.2006.08.002

Van Kouwen, 2005, FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis, Eur J Nucl Med Mol Imaging, 32, 399, 10.1007/s00259-004-1689-4

Friess, 1995, Diagnosis of pancreatic cancer by 2-fluoro-2-deoxy-D-glucose positron emission tomography, Gut, 36, 771, 10.1136/gut.36.5.771

Nakamoto, 1999, Autoimmune pancreatitis with F-18 fluoro-2-deoxy-D-glucose PET findings, Clin Nucl Med, 24, 778, 10.1097/00003072-199910000-00009

Buck, 2001, Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?, J Nucl Med, 42, 721

Torisani, 2002, Mécanismes moléculaires de la cancérogenèse pancréatique, Ann Pathol, 22, 349

Maire, 2008, Intraductal papillary mucinous neoplasms of the pancreas: performance of pancreatic fluid analysis for positive diagnosis and the prediction of malignancy, Am J Gastroenterol, 103, 2871, 10.1111/j.1572-0241.2008.02114.x

Heinrich, 2005, Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness, Ann Surg, 242, 235, 10.1097/01.sla.0000172095.97787.84

Casneuf, 2007, Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?, Acta Gastroenterol Belg, 70, 331

Saif, 2008, 18F-FDG positron emission tomography CT (FDG PET–CT) in the management of pancreatic cancer: initial experience in 12 patients, J Gastrointest Liver Dis, 17, 173

Wakasabayashi, 2008, Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer, World J Gastroenterol, 14, 64, 10.3748/wjg.14.64

Bipat, 2005, Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis, J Comput Assist Tomogr, 29, 438, 10.1097/01.rct.0000164513.23407.b3

Bang, 2006, The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography n the differential diagnosis, staging, and response evaluation after concurrent chemradiotherapy for pancreatic cancer, J Clin Gastroenterol, 40, 923, 10.1097/01.mcg.0000225672.68852.05

Nishiyama, 2005, Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer, Ann Nucl Med, 19, 491, 10.1007/BF02985577

Diederichs, 2000, Values and limitations of 18F-fluorodeoxyglucose positron emission tomography with preoperative evaluation of patients with pancreatic masses, Pancreas, 20, 109, 10.1097/00006676-200003000-00001

Thésaurus national de cancérologie digestive. Société nationale française de gastroentérologie 2008; www.snfge.asso.fr.

Nakata, 1997, 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma, Cancer, 79, 695, 10.1002/(SICI)1097-0142(19970215)79:4<695::AID-CNCR6>3.0.CO;2-D

Nakata, 2001, Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer, Int J Oncol, 19, 53

Ducreux, 2003, La tomographie par émission de positons en cancérologie digestive, Gastroenterol Clin Biol, 27, 71

Brucher, 2001, Neoadjuvant chemotherapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography, Ann Surg, 233, 300, 10.1097/00000658-200103000-00002

Flamen, 2002, Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced esophageal cancer, Ann Oncol, 13, 361, 10.1093/annonc/mdf081

Rose, 1999, 18-fluorodeoxyglucose positron emission tomography in the management of patients with suspected pancreatic cancer, Ann Surg, 229, 729, 10.1097/00000658-199905000-00016

Maisey, 2000, FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study, Br J Cancer, 83, 287, 10.1054/bjoc.2000.1166

Ruf, 2005, Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI, Pancreatology, 5, 266, 10.1159/000085281

Malka, 2002, Risk of pancreatic adenocarcinoma in chronic pancreatitis, Gut, 51, 849, 10.1136/gut.51.6.849

Lowenfels, 2000, Risk factors for cancer in hereditary pancreatitis, Med Clin North Am, 84, 565, 10.1016/S0025-7125(05)70240-6

Imdahl, 1999, Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer, Br J Surg, 86, 194, 10.1046/j.1365-2168.1999.01016.x

Zimny, 1997, Fluorine-18-fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases, Eur J Nucl Med, 24, 678

Lévy, 2008, Diagnostic challenge in autoimmune pancreatitis: beware of shipwreck, Gut, 57, 1646, 10.1136/gut.2008.158972

Ozaki, 2008, Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18-fluorodeoxyglucose positron emission tomography, J Gastroenterol, 43, 144, 10.1007/s00535-007-2132-y

Nakajo, 2007, The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions, Eur J Nucl Med Mol Imaging, 34, 2088, 10.1007/s00259-007-0562-7

Sperti, 2001, Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas, Ann Surg, 234, 675, 10.1097/00000658-200111000-00014

Sperti, 2007, 18-fluorodeoxyglucose positron emission tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas, Ann Surg, 246, 932, 10.1097/SLA.0b013e31815c2a29

Baiocchi, 2008, Possible additional value of 18-FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: preliminary results, J Exp Clin Cancer Res, 27, 10, 10.1186/1756-9966-27-10

Sato, 2006, High F-18 fluorodeoxyglucose accumulation in solid pseudopapillary tumors of the pancreas, Ann Nucl Med, 20, 431, 10.1007/BF03027379

Lee, 2005, Detection of a solid pseudopapillary tumor of the pancreas with F-18 FDG positron emission tomography, Clin Nucl Med, 30, 187, 10.1097/00003072-200503000-00010

Cadiot, 2003, Stratégie diagnostique des tumours duodénopancréatiques, Gastroenterol Clin Biol, 27, 6

Dromain, 2006, Stratégie d’explorations radiologiques pour le bilan d’extension et la surveillance des tumeurs endocrines, Bull Cancer, 93, 1183

Adams, 1998, Limited value of fluorine-18-fluodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours, Eur J Nucl Med, 25, 79, 10.1007/s002590050197

Toshikuni, 2008, Nonfunctioning endocrine pancreatic tumor examined with 18F-FDG PET/CT, Ann Nucl Med, 22, 133, 10.1007/s12149-007-0085-0

Pasquali, 1998, Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?, World J Surg, 22, 588, 10.1007/s002689900439

Nakamoto, 2000, Evaluation of pancreatic islet cell tumors by fluorine-18-fluorodeoxyglucose positron emission tomography: comparison with other modalities, Clin Nucl Med, 25, 115, 10.1097/00003072-200002000-00007

Proye, 1988, Imagerie préopératoire des insulinomes de l’adulte. Fiabilité-rentabilité, Ann Chir, 42, 391

Kauhanen, 2007, Fluorine-18-L-Dihydroxyphenylalanine (18F-DOAP) positron emission tomography as a tool to localize an insulinoma or β-cell hyperplasia in adults patients, J Clin Endocrinol Metab, 92, 1237, 10.1210/jc.2006-1479

Montravers, 2006, Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?, J Nucl Med, 47, 1455

Diederichs, 1998, FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies, J Nucl Med, 39, 1030

Bourguet, 2006, Bull Cancer, 93, 1228